Every material Form 8-K MACROGENICS INC has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 30, 2026, MacroGenics increased its Board from ten to eleven members and appointed Michael Vasconcelles and Emil Kuriakose as independent directors, effective that day. Both were also placed on the Science and Technology Committee and will receive director compensation, including initial option and restricted stock unit awards, which adds modest equity dilution for shareholders. The filing reports no financial results.
Board size increased from ten to eleven members, approved October 30, 2026.
Michael Vasconcelles named Class II Director and Emil Kuriakose named Class III Director, effective October 30, 2026.
Each director receives an option for 44,000 shares and a restricted stock unit grant for 7,500 shares under the 2023 Equity Incentive Plan.
Both directors were determined to be independent and joined the Science and Technology Committee.
MacroGenics presented interim Phase 1 data for MGC026, an investigational B7-H3-directed antibody-drug conjugate, at the ESMO 2026 Congress on October 23, 2026. In 22 response-evaluable head and neck cancer patients, the best overall response rate was 27% (6/22), and the company plans a front-line study combining MGC026 with pembrolizumab in early 2027. The data are preliminary, and the filing discloses no revenue, earnings or financing figures.
Best overall response rate of 27% (6/22) in the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort, including four confirmed and two unconfirmed partial responses
Grade 3 or higher treatment-related adverse events occurred in 51% of the 85-patient overall safety population, and 5% discontinued treatment
Plans to start a front-line SCCHN expansion cohort with pembrolizumab in early 2027; updated Stage 2 data expected in mid-2027
MacroGenics reported second-quarter 2026 revenue of $32.8 million, up from $6.9 million a year earlier, and net income of $19.5 million, compared with a net loss of $36.3 million. The profit reflects $89.2 million of income from discontinued operations tied to the sale of its manufacturing operations, while the loss from continuing operations widened to $69.6 million, including a $52.8 million non-cash loss on extinguishing a royalty monetization liability.
Q2 2026 total revenue was $32.8 million, versus $6.9 million in Q2 2025, driven mainly by a $24.5 million Sanofi regulatory milestone.
Net income was $19.5 million, or $0.31 per share, versus a net loss of $36.3 million, or $0.57 per share, a year earlier.
Loss from continuing operations was $69.6 million, compared with $42.7 million a year earlier, after a $52.8 million non-cash loss on extinguishment of the ZYNYZ royalty monetization liability.
Pro forma cash, cash equivalents and marketable securities were $327 million, and the company guides cash runway through 2028.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MACROGENICS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →